# South America Liquid Biopsy Market

> South America Liquid Biopsy Market Research Report By Types (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, Others), By Application (Cancer Therapeutic Application, Reproductive Health, Others) and By Sample (Blood Sample, Urine Sample, Other) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.52%
- **2024:** $ 727.92 Million
- **2025:** $ 804.5 Million
- **2035:** $ 2,187.44 Million
- **Key Players:** Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US)

**Report ID:** MRFR/HC/42982-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-liquid-biopsy-market-44662

---

## Market Summary

## **South America Liquid Biopsy Market Overview**

As per MRFR analysis, the South America Liquid Biopsy Market Size was estimated at 823.38 (USD Million) in 2023.The South America Liquid Biopsy Market Industry is expected to grow from 910.0(USD Million) in 2024 to 2,734.26 (USD Million) by 2035. The South America Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.519% during the forecast period (2025 - 2035)

### **Key South America Liquid Biopsy Market Trends Highlighted**

The South America Liquid Biopsy Market is experiencing several key trends driven by advancements in technology and rising healthcare demands. One significant market driver is the increasing prevalence of cancer and other chronic diseases within the region, prompting the need for more efficient and less invasive diagnostic methods. Governments across South America are recognizing the importance of early detection in improving patient outcomes and are investing in healthcare infrastructure to support research and development in liquid biopsy technologies.

Furthermore, there has been a notable shift towards personalized medicine, where liquid biopsies play a crucial role in identifying specific genetic mutations, allowing for tailored treatment options for patients. Opportunities within this market are vast, particularly in improving access to liquid biopsy tests in rural and underserved areas. The South American healthcare sector is increasingly focused on integrating advanced diagnostic tools to enhance patient management, presenting a unique chance for companies to introduce innovative solutions.

Collaborative ventures between local healthcare providers and universities are gaining momentum, which could further accelerate the adoption of liquid biopsy techniques across Brazil, Argentina, and Chile. In recent times, the trend of regulatory support for liquid biopsy products evident, as South American regulatory bodies are working on establishing clear guidelines to facilitate their approval and usage in clinical settings. The rise of telemedicine during the pandemic has also contributed to the growth of remote diagnostics, where patients can receive testing and results without needing to visit healthcare facilities.

These trends indicate that the South America Liquid Biopsy Market is evolving quickly, driven by technological advancements, regulatory support, and increasing awareness of personalized healthcare solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Liquid Biopsy Market Drivers**

### **Rising Incidence of Cancer in South America**

The South America Liquid Biopsy Market Industry is witnessing significant growth driven by the rising incidence of cancer across the region. According to health authorities in South America, cancer cases have been reported to increase by approximately 11% over the past five years. Brazil, being the largest country in the region, has seen a steady rise in cancer diagnoses, with the National Cancer Institute reporting nearly 600,000 new cases annually.

The sharp increase in cancer patients highlights the increasing demand for non-invasive diagnostic methods, such as liquid biopsies that can provide real-time insights into tumor dynamics. Organizations like the Brazilian Society of Oncology play a crucial role in promoting awareness about cancer screening and novel diagnostic approaches, fueling the adoption of liquid biopsies as a vital tool for early detection and monitoring of various cancers.

### **Technological Advancements in Diagnostics**

The South America Liquid Biopsy Market Industry is strongly influenced by rapid advancements in liquid biopsy technologies, which enhance the accuracy and efficacy of cancer diagnostics. Innovative companies within the region are developing more sophisticated methods for isolating and analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), leading to improved sensitivity in detecting malignancies at earlier stages.

For instance, patents filed by leading biotech firms indicate significant progress in liquid biopsy methods in South America, allowing for more comprehensive genomic profiling.These technological advancements not only provide clinicians with better diagnostic tools but also improve patient outcomes, spurring further investment and growth in the market.

### **Supportive Government Initiatives and Health Policies**

Government initiatives across South America are increasingly supporting the adoption of liquid biopsies as part of broader healthcare advancements. For example, health ministries in countries like Argentina and Colombia are funding initiatives aimed at integrating advanced diagnostic techniques into national cancer care programs. This includes allocating budgets for the research and development of liquid biopsy technologies.

The Brazilian government's commitment to enhancing cancer screening and diagnosis aligns with this trend, as evidenced by public health campaigns emphasizing early detection.Such supportive policies not only create a conducive environment for growth in the South America Liquid Biopsy Market Industry but also ensure better access to innovative diagnostic solutions, benefiting healthcare facilities and patients alike.

## **South America Liquid Biopsy Market Segment Insights**

### **Liquid Biopsy Market Types Insights**

The South America Liquid Biopsy Market is witnessing profound growth as it encompasses different types of diagnostic approaches that utilize body fluids, making cancer detection and monitoring less invasive and more efficient. Among these methods, circulating tumor cells (CTCs) have garnered significant attention for their capacity to provide real-time insights into tumor dynamics. CTCs represent a pivotal area in personalized medicine, enabling clinicians to adapt treatment plans based on the evolving characteristics of tumors.

Circulating tumor DNA (ctDNA) has emerged as another key player, representing tumor-specific genetic alterations found in the bloodstream, which can assist in early detection and monitoring the response to therapy. The significance of ctDNA lies in its ability to guide treatment decisions without the need for invasive tissue biopsies, making it an attractive alternative for both patients and oncologists. Extracellular vesicles, including exosomes, are also gaining traction as they can carry biomolecules such as RNA and proteins that reflect the tumor's molecular profile; this opens avenues for new biomarker discovery and understanding tumor microenvironments.

Lastly, other methods not directly categorized into the aforementioned types hold varying degrees of importance, exploring innovative diagnostics and treatment monitoring strategies. The South American market's segmentation reflects diverse needs, with advancements in liquid biopsy technologies driving regional acceptance and application. As healthcare infrastructure improves across South American countries, the adoption of these innovative liquid biopsy types is likely to expand, offering improved patient management and outcomes while also contributing to the overall South America Liquid Biopsy Market revenue growth.

The trends point towards a coordinated effort , together with emerging technologies, position the South America Liquid Biopsy Market favorably in the global landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Liquid Biopsy Market Application Insights**

The South America Liquid Biopsy Market is poised for significant growth, primarily driven by its application in various healthcare sectors. The Application segment consists of critical areas such as Cancer Therapeutic Application and Reproductive Health, which play pivotal roles in advancing diagnostic and treatment methodologies. Cancer Therapeutic Application is particularly crucial as early detection through liquid biopsy can facilitate timely interventions, potentially improving patient outcomes.

Reproductive Health is also gaining traction, providing valuable insights into prenatal diagnostics and fertility assessments, which are increasingly essential in the region’s evolving healthcare landscape.Additionally, the flexibility offered by liquid biopsies allows for continuous monitoring, which is an advantage over traditional biopsy methods. The growth in these applications responds to the increasing demand for non-invasive testing solutions and personalized medicine. Overall, the South America Liquid Biopsy Market is anticipated to grow significantly as the healthcare industry increasingly embraces innovative technologies for improved diagnostics and treatment strategies.

The market benefits from favorable regulatory frameworks that support advanced medical technologies and the translation of research into clinical practice, ultimately enhancing patient care across the region.

### **Liquid Biopsy Market Sample Insights**

The South America Liquid Biopsy Market is seeing significant advancements in the Sample segment, which includes Blood, Urine, and Other samples used for non-invasive cancer diagnostics and monitoring. Blood samples, typically preferred for their extensive data accuracy and reliability, dominate this segment due to their ability to detect circulating tumor DNA and biomarkers. With a growing focus on early cancer detection and personalized medicine, these blood tests have become essential in clinical settings.

Urine samples, though less common than blood, are gaining traction owing to their ease of collection and the potential to identify specific biomarkers for bladder and other cancers.The Other category encompasses diverse sample types that may include saliva or cerebrospinal fluid, presenting unique opportunities for specialized diagnostics. The rising demand for minimally invasive procedures in South America, supported by technological innovations, positions the Sample segment as a crucial area for growth in the liquid biopsy field.

As healthcare professionals and patients alike recognize the benefits of liquid biopsy, the South America Liquid Biopsy Market is likely to witness an upward trend, indicating healthy prospects improving patient outcomes.

## **South America Liquid Biopsy Market Key Players and Competitive Insights**

The South America Liquid Biopsy Market is an emerging arena characterized by rapid advancements in technology and increasing interest from both healthcare providers and patients. Liquid biopsy, as a non-invasive procedure to detect cancer biomarkers in body fluids, is gaining nearly universal acceptance due to its potential to provide early-stage diagnosis and treatment monitoring. As the healthcare landscape evolves in this region, several companies are competing for market share by offering innovative solutions tailored to the specific needs of the South American population.

Competitive dynamics in this market are influenced by factors such as technological innovation, regulatory approvals, reimbursement policies, and growing partnerships among stakeholders, including research institutions and diagnostic laboratories.OncoOne is making significant strides in the South America Liquid Biopsy Market, leveraging its expertise in the development of innovative cancer diagnostics. The company has a strong focus on the early detection of cancer through its proprietary biomarker platform. One of the standout strengths of OncoOne is its commitment to research and development, which enables the introduction of groundbreaking diagnostic tools that can significantly enhance patient outcomes.

The firm has established collaborations with local healthcare entities, which have bolstered its market presence and helped tailor its products to meet the specific needs of South American healthcare systems. Furthermore, OncoOne's awareness of regional regulations and its ability to navigate these landscapes effectively have positioned it favorably in a competitive environment dominated by several players.In the South America Liquid Biopsy Market, NeoGenomics stands out as a robust competitor, with a focus on specialized cancer diagnostics and comprehensive molecular services that cater to various tumor types through liquid biopsy technologies.

The company’s diverse product offerings include genomic tests that facilitate personalized cancer treatment, and its growing presence in South America is backed by strategic investments in infrastructure and technology. of NeoGenomics encompass an extensive network of partnerships with regional healthcare providers and ongoing efforts in research and development to stay ahead of market needs. Furthermore, NeoGenomics has engaged in strategic mergers and acquisitions to enhance its capabilities and broaden its service portfolio within South America, thus delivering reliable and accessible liquid biopsy solutions that contribute to improved patient management and outcomes.

### **Key Companies in the South America Liquid Biopsy Market Include**

## **South America Liquid Biopsy Market Industry Developments**

The South America Liquid Biopsy Market has witnessed several significant developments recently. In September 2023, OncoOne announced the advancement of its liquid biopsy platform intended for early cancer detection, enhancing its research partnerships across Brazil and Argentina. In August 2023, NeoGenomics expanded its presence in the region by opening a new laboratory facility in So Paulo, aimed at increasing testing capabilities and enhancing patient access to advanced oncology diagnostics. The market is also characterized by a growing valuation, with companies like Illumina and Guardant Health showcasing promising revenue increases attributed to the rising demand for non-invasive cancer diagnostics.

Moreover, in July 2023, a strategic partnership was formed between Roche and Fulgent Genetics to enhance liquid biopsy product offerings tailored for South American patients. Continuous technological innovations in liquid biopsy diagnostics are driving market growth as healthcare providers increasingly adopt these solutions for better patient management. In the past few years, significant regulatory advancements in Brazil facilitated the approval processes of novel liquid biopsy tests, indicating a positive trajectory for market participants including Thermo Fisher Scientific and Exact Sciences.

## **South America Liquid Biopsy Market Segmentation Insights**

### **Liquid Biopsy Market****Types****Outlook**

### **Liquid Biopsy Market****Application****Outlook**

### **Liquid Biopsy Market****Sample****Outlook**

## Market Drivers

### Rising Incidence of Cancer

The increasing incidence of cancer in South America is a primary driver for the liquid biopsy market. According to recent statistics, cancer cases are projected to rise by approximately 20% over the next decade in the region. This alarming trend necessitates innovative diagnostic solutions, such as liquid biopsies, which offer non-invasive testing options. Liquid biopsies can detect circulating tumor DNA (ctDNA) and other biomarkers, enabling early diagnosis and personalized treatment plans. As healthcare providers seek to improve patient outcomes, the demand for liquid biopsy technologies is expected to surge. Furthermore, the liquid biopsy market is likely to benefit from collaborations between research institutions and healthcare organizations aimed at developing advanced diagnostic tools tailored to the unique needs of the South American population.

### Regulatory Framework Enhancements

Enhancements in the regulatory framework surrounding diagnostic tools are fostering growth in the liquid biopsy market in South America. Regulatory bodies are increasingly recognizing the importance of liquid biopsies as viable diagnostic options, leading to streamlined approval processes for new technologies. This supportive environment encourages innovation and investment in the development of liquid biopsy solutions. Countries like Chile and Colombia are actively working to establish clear guidelines for the use of liquid biopsies in clinical practice, which could further stimulate market growth. As regulatory frameworks become more conducive to the adoption of these technologies, the liquid biopsy market is expected to flourish, potentially reaching a market size of $500 million by 2028.

### Investment in Healthcare Infrastructure

Investment in healthcare infrastructure across South America is significantly influencing the liquid biopsy market. Governments and private entities are increasingly allocating funds to enhance healthcare facilities, which includes the integration of advanced diagnostic technologies. For instance, Brazil and Argentina have initiated programs to modernize laboratories and improve access to cutting-edge diagnostic tools. This investment is expected to facilitate the adoption of liquid biopsy technologies, as healthcare providers will have the necessary resources to implement these innovative solutions. The liquid biopsy market could see a compound annual growth rate (CAGR) of around 15% in the coming years, driven by improved healthcare infrastructure and increased accessibility to diagnostic services.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine in South America is a significant driver for the liquid biopsy market. As healthcare professionals increasingly recognize the importance of tailoring treatments to individual patients, liquid biopsies provide a valuable tool for monitoring treatment responses and detecting disease recurrence. This approach not only enhances patient care but also aligns with the broader trend of precision medicine. The liquid biopsy market is expected to expand as more healthcare providers adopt these technologies to facilitate personalized treatment plans. Market analysts predict that the demand for personalized medicine could lead to a 25% increase in liquid biopsy utilization over the next five years, reflecting a growing commitment to individualized patient care.

### Technological Innovations in Diagnostic Tools

Technological innovations in diagnostic tools are propelling the liquid biopsy market forward in South America. Advances in sequencing technologies, bioinformatics, and data analysis are enhancing the accuracy and efficiency of liquid biopsies. For example, the development of next-generation sequencing (NGS) has revolutionized the ability to analyze ctDNA and other biomarkers from blood samples. This progress not only improves diagnostic capabilities but also reduces turnaround times for results, making liquid biopsies more appealing to healthcare providers. As these technologies continue to evolve, the liquid biopsy market is likely to experience substantial growth, with projections indicating a potential market value increase of up to $1 billion by 2030.

## Future Outlook

The [Liquid Biopsy Market](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) is projected to grow at a 10.52% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and demand for non-invasive diagnostics.

**New opportunities:**

- Development of portable liquid biopsy devices for remote diagnostics
- Partnerships with healthcare providers for integrated testing solutions
- Expansion into emerging markets with tailored pricing strategies

By 2035, the liquid biopsy market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Cancer Diagnosis (Largest) vs. Treatment Monitoring (Fastest-Growing)

In the application segment of the liquid biopsy market, Cancer Diagnosis holds the largest market share, reflecting its critical role in early detection and treatment planning. Following closely, Treatment Monitoring is gaining traction as an essential tool for assessing treatment efficacy and disease progression, contributing significantly to the overall market landscape. Recurrence Monitoring and Clinical Trials are also notable, but they occupy smaller portions of the market share as research applications continue to evolve and develop new innovations.

Growth trends in this segment are driven by technological advancements in liquid biopsy techniques, increasing cancer prevalence, and a growing focus on personalized medicine. The rising demand for non-invasive diagnostic methods propels both Cancer Diagnosis and Treatment Monitoring, with Treatment Monitoring appearing as the fastest-growing segment due to ongoing research and clinical emphasis. The expanding application of liquid biopsy in clinical trials bolsters its relevance and market adoption, which supports the demand for innovative solutions in cancer care.

Cancer Diagnosis (Dominant) vs. Treatment Monitoring (Emerging)

Cancer Diagnosis is a dominant segment in the liquid biopsy application landscape, primarily due to its established methodology in identifying cancer at its earliest stages, enhancing patient outcomes through timely intervention. This segment benefits from growing awareness and acceptance among healthcare professionals and patients alike, facilitating its widespread integration into clinical settings. On the other hand, Treatment Monitoring is emerging as a significant player, fueled by advancements in technology and the necessity for real-time tracking of treatment responses. This dual focus offers a dynamic interplay within the market, where Cancer Diagnosis leads in established applications while Treatment Monitoring is rapidly evolving, capturing the attention of researchers and clinicians aiming for more effective cancer management strategies.

### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing)

In the South America liquid biopsy market, the distribution of sample types showcases Blood as the dominant player, accounting for a substantial share due to its widespread acceptance in clinical settings and the ability to provide comprehensive insights into a patient's health. Urine, while currently smaller in market share, is emerging rapidly, driven by advancements in technology and a growing preference for non-invasive testing options.

The growth trends in this segment indicate a significant shift towards more accessible and less invasive diagnostic methods. With ongoing research and development focusing on urine and saliva, these sample types are expected to gain traction. Additionally, increasing awareness among healthcare providers and patients regarding the benefits of liquid biopsies is propelling the market forward, particularly for urine samples that are viewed as the future of non-invasive testing.

Blood (Dominant) vs. Urine (Emerging)

Blood remains the dominant sample type in the South America liquid biopsy market due to its established role in diagnostics and comprehensive information yield. It is preferred for its reliability, providing crucial data for cancer detection and monitoring. In contrast, urine is an emerging sample type recognized for its less invasive collection process, making it a patient-friendly alternative. Its potential for early disease detection and monitoring, combined with technological advancements, is drawing significant interest. As research continues to evolve, urine is positioned to capture a larger share of the market, especially as its effectiveness in liquid biopsy applications is validated further.

### By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing)

The Technology segment in the South America liquid biopsy market consists of several key areas, with Next Generation Sequencing (NGS) holding the largest market share due to its advanced analytical capabilities and widespread application in oncology. Digital PCR follows closely as it gains traction among researchers and clinicians for its ability to provide highly sensitive quantification of nucleic acids. Microfluidics, Exosome Isolation, and Circulating Tumor Cells are essential components, each promising unique applications, yet currently contribute smaller shares to the overall market. 

Growth trends in this Technology segment are significantly influenced by the increasing prevalence of cancer and the rising demand for non-invasive diagnostic methods. The technological advancements in NGS and Digital PCR underscore the potential for rapid market evolution, driven by continual innovations and the expanding acceptance of liquid biopsies in clinical practices. As healthcare providers look for more precise solutions, the focus is on enhancing diagnostic accuracy and early detection capabilities, fueling the adoption of these technologies.

Technology: Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging)

Next Generation Sequencing (NGS) is a dominant force in the Technology segment, characterized by its high throughput and ability to analyze multiple biomarker targets simultaneously, making it invaluable in cancer diagnostics and personalized medicine. Its leadership position is complemented by a strong infrastructure supporting research and development. In contrast, Digital PCR is an emerging technology gaining momentum due to its unparalleled sensitivity and accuracy, particularly in quantifying low-abundance targets. This advancement aligns well with the increasing need for precise applications in diagnostics and monitoring disease progression. Both technologies are poised for growth, though NGS's established presence contrasts with Digital PCR's rapid innovation and adoption, which is reshaping the landscape of liquid biopsy applications.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The End Use segment of the liquid biopsy market has shown significant diversity, with hospitals holding the largest share due to their central role in patient care and diagnostics. In contrast, diagnostic laboratories are rapidly gaining traction as they capitalize on advancements in technology and increasing demand for precise diagnostic solutions. Both segments enhance the overall efficiency of healthcare delivery in South America.

Growth trends in this segment are driven by the increasing prevalence of cancer and other chronic diseases, leading to a higher demand for early diagnosis and personalized treatment options. Hospitals remain a cornerstone for patient management, while diagnostic laboratories are poised for rapid growth, fueled by innovations and the need for specialized testing services. The rising investment in healthcare infrastructure further supports this dynamic growth in the End Use segment.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals play a dominant role in the liquid biopsy market as they are critical providers of healthcare services, offering a broad range of diagnostic tests including liquid biopsies. Their established infrastructure and patient base allow them to effectively integrate these technologies into standard care practices. On the other hand, diagnostic laboratories are emerging as key players due to their specialized focus on diagnostics and testing services that cater to specific health conditions. They are increasingly adopting innovative techniques in liquid biopsy testing, thus positioning themselves favorably in the market. This contrasts with hospitals, where liquid biopsy tests may compete with a wider array of diagnostic methods. As the market evolves, both segments will continue to shape the landscape of liquid biopsy applications.

## Regional Market Share Analysis

### Brazil : Strong Growth Driven by Innovation

Key markets within Brazil include São Paulo, Rio de Janeiro, and Minas Gerais, where healthcare facilities are increasingly adopting liquid biopsy technologies. The competitive landscape features major players like Guardant Health and Roche, which have established a strong presence through partnerships and local collaborations. The business environment is favorable, with a growing emphasis on personalized medicine and oncology applications, driving demand for liquid biopsy solutions.

### Mexico : Growing Demand and Investment Opportunities

Key cities such as Mexico City and Guadalajara are pivotal in the liquid biopsy landscape, hosting numerous healthcare institutions and research centers. The competitive environment includes players like Exact Sciences and Thermo Fisher Scientific, which are actively expanding their market presence. The local market dynamics are characterized by a growing emphasis on precision medicine, with liquid biopsies being integrated into routine clinical practices, particularly in oncology.

### Argentina : Focus on Cancer Detection Innovations

Key markets in Argentina include Buenos Aires and Córdoba, where healthcare facilities are adopting liquid biopsy technologies at an increasing rate. The competitive landscape features companies like Foundation Medicine and Illumina, which are establishing partnerships with local healthcare providers. The business environment is improving, with a focus on integrating liquid biopsy solutions into oncology practices, thereby enhancing patient care and treatment outcomes.

### Rest of South America : Regional Growth with Unique Challenges

Key markets in this sub-region include Santiago, Bogotá, and Lima, where healthcare systems are beginning to adopt liquid biopsy technologies. The competitive landscape is diverse, with both local and international players like Biocept and GRAIL entering the market. Local dynamics are influenced by varying healthcare policies and economic conditions, which can impact the adoption of liquid biopsy solutions across different countries.

## Competitive Benchmarking

The liquid biopsy market in South America is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for non-invasive diagnostic solutions. Key players such as Guardant Health (US), Roche (CH), and Illumina (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Guardant Health (US) focuses on expanding its product offerings and enhancing its genomic profiling capabilities, while Roche (CH) emphasizes integrating liquid biopsy solutions into its existing diagnostic portfolio, thereby strengthening its competitive positioning. Illumina (US) is actively pursuing collaborations to enhance its sequencing technologies, which collectively shape a competitive environment that is increasingly reliant on innovation and strategic alliances.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to better serve the South American market. The competitive structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set industry standards and drive technological advancements that smaller firms may struggle to match.

In October  Guardant Health (US) announced a partnership with a leading South American healthcare provider to enhance access to its liquid biopsy tests. This strategic move is likely to expand its market reach and improve patient access to advanced diagnostic tools, thereby reinforcing its position in the region. The partnership underscores the importance of local collaborations in navigating regulatory landscapes and addressing specific market needs.

In September  Roche (CH) launched a new liquid biopsy assay aimed at early cancer detection, which is expected to significantly impact patient outcomes. This initiative not only showcases Roche's commitment to innovation but also positions the company as a leader in the early detection segment, potentially capturing a larger share of the market. The introduction of this assay reflects a broader trend towards personalized medicine and early intervention strategies.

In August  Illumina (US) unveiled a new platform designed to streamline the analysis of liquid biopsy samples, enhancing throughput and accuracy. This technological advancement is crucial as it addresses the growing demand for efficient and reliable diagnostic solutions. By improving the analytical capabilities of liquid biopsies, Illumina (US) is likely to strengthen its competitive edge and attract a wider customer base.

As of November  current trends in the liquid biopsy market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards innovation, technological advancements, and supply chain reliability becoming paramount. This transition suggests that companies that prioritize R&D and strategic partnerships will likely emerge as leaders in the market.

## Recent News & Developments

The South America Liquid Biopsy Market has witnessed several significant developments recently. In September 2023, OncoOne announced the advancement of its liquid biopsy platform intended for early cancer detection, enhancing its research partnerships across Brazil and Argentina. In August 2023, NeoGenomics expanded its presence in the region by opening a new laboratory facility in So Paulo, aimed at increasing testing capabilities and enhancing patient access to advanced oncology diagnostics. The market is also characterized by a growing valuation, with companies like Illumina and Guardant Health showcasing promising revenue increases attributed to the rising demand for non-invasive cancer diagnostics.

Moreover, in July 2023, a strategic partnership was formed between Roche and Fulgent Genetics to enhance liquid biopsy product offerings tailored for South American patients. Continuous technological innovations in liquid biopsy diagnostics are driving market growth as healthcare providers increasingly adopt these solutions for better patient management. In the past few years, significant regulatory advancements in Brazil facilitated the approval processes of novel liquid biopsy tests, indicating a positive trajectory for market participants including Thermo Fisher Scientific and Exact Sciences.

## Report Scope

| MARKET SIZE 2024 | 727.92(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 804.5(USD Million) |
| MARKET SIZE 2035 | 2187.44(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US) |
| Segments Covered | Application, Sample Type, Technology, End Use |
| Key Market Opportunities | Emerging technologies in liquid biopsy enhance early cancer detection and personalized treatment options. |
| Key Market Dynamics | Rising demand for non-invasive cancer diagnostics drives innovation in liquid biopsy technologies across South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What was the overall market valuation of the liquid biopsy market in 2024?**
A: The overall market valuation was $727.92 Million in 2024.

**Q: What is the projected market valuation for the liquid biopsy market by 2035?**
A: The projected market valuation for 2035 is $2187.44 Million.

**Q: What is the expected CAGR for the liquid biopsy market during the forecast period 2025 - 2035?**
A: The expected CAGR for the liquid biopsy market during the forecast period 2025 - 2035 is 10.52%.

**Q: Which application segment had the highest valuation in 2024?**
A: In 2024, the Cancer Diagnosis application segment had the highest valuation at $145 Million.

**Q: What is the projected valuation for the Treatment Monitoring segment by 2035?**
A: The projected valuation for the Treatment Monitoring segment by 2035 is $360 Million.

**Q: Which sample type is expected to show significant growth in the liquid biopsy market?**
A: The Blood sample type is expected to show significant growth, with a projected valuation of $450 Million by 2035.

**Q: What technology segment is anticipated to lead the market in the coming years?**
A: The Next Generation Sequencing technology segment is anticipated to lead the market, with a projected valuation of $450 Million by 2035.

**Q: Which end-use segment is expected to have the highest valuation by 2035?**
A: The Pharmaceutical Companies end-use segment is expected to have the highest valuation, projected at $817.44 Million by 2035.

**Q: Who are the key players in the liquid biopsy market?**
A: Key players in the liquid biopsy market include Guardant Health, Exact Sciences, Freenome, GRAIL, Biocept, Foundation Medicine, Roche, Thermo Fisher Scientific, and Illumina.

**Q: What trends are influencing the growth of the liquid biopsy market in South America?**
A: Trends influencing growth include advancements in technology, increasing demand for non-invasive diagnostic methods, and rising investments from key players.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-liquid-biopsy-market-44662*